Renal Denervation in Isolated Systolic Hypertension Using Different Catheter Techniques and Technologies.

Patients with isolated systolic hypertension (ISH) are thought to show a diminished blood pressure (BP)-lowering effect after renal sympathetic denervation (RDN). This conclusion is mostly derived from unipolar radiofrequency catheter ablation studies. Limited data for newer RDN technologies exist. We used data from the RADIOSOUND-HTN (Three-Arm Randomized Trial of Different Renal Denervation Devices and Techniques in Patients With Resistant Hypertension) comparing 3 different RDN approaches to investigate a possible interaction between ISH and RDN response. One hundred twenty patients were stratified by having ISH or combined systolic-diastolic hypertension (CH). Of these, 39 underwent radiofrequency ablation of the renal main arteries, 39 combined radiofrequency ablation of the main and branch arteries, and 42 were treated with ultrasound-based ablation of the main renal artery. Patients with ISH (n=61) were older and had lower systolic and diastolic BP on ambulatory measurement (ambulatory BP measurement) at baseline in comparison to CH (n=59). At 3 months, patients with ISH showed a less pronounced BP-lowering effect of RDN as compared to patients with CH (daytime average -5.9±11.8 versus -13.3±11.7 mm Hg, P=0.001). This difference was significant for radiofrequency ablation of the renal main arteries and ultrasound-based ablation of the main renal artery treatment but did not reach significance in the radiofrequency ablation of the main and branch arteries group. After adjustment for baseline BP values and age, there was no significant difference in BP reduction between ISH and CH. Using unadjusted BP values, RDN seems to be more effective in CH than in ISH. However, adjusting for baseline BP values revealed similar BP reduction in ISH and CH patients, irrespective of the RDN treatment used. The value of ISH as predictor for successful RDN might have been overestimated in the past. Clinical Trial Registration- URL: http://www.clinicaltrials.gov . Unique identifier: NCT02920034.

[1]  K. Kario,et al.  Seasonal variation in blood pressure: Evidence, consensus and recommendations for clinical practice. Consensus statement by the European Society of Hypertension Working Group on Blood Pressure Monitoring and Cardiovascular Variability. , 2020, Journal of hypertension.

[2]  Ambulatory Blood Pressure Monitor , 2019, Biomedical Safety & Standards.

[3]  H. Thiele,et al.  A Three-Arm Randomized Trial of Different Renal Denervation Devices and Techniques in Patients With Resistant Hypertension (RADIOSOUND-HTN) , 2019, Circulation.

[4]  Corrigendum to: 2018 ESC/ESH Guidelines for the management of arterial hypertension. , 2018, European heart journal.

[5]  Thomas Kahan,et al.  2018 ESC/ESH Guidelines for the management of arterial hypertension. , 2018, European heart journal.

[6]  H. Thiele,et al.  Predictors for profound blood pressure response in patients undergoing renal sympathetic denervation , 2018, Journal of hypertension.

[7]  S. Pocock,et al.  Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial , 2018, The Lancet.

[8]  K. Peter,et al.  Ambulatory arterial stiffness index as a predictor of blood pressure response to renal denervation* , 2018, Journal of hypertension.

[9]  Neil Chapman,et al.  Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial , 2018, The Lancet.

[10]  M. Quail,et al.  Cardiac magnetic resonance assessment of central and peripheral vascular function in patients undergoing renal sympathetic denervation as predictor for blood pressure response , 2018, Clinical Research in Cardiology.

[11]  José R. Banegas,et al.  Relationship between Clinic and Ambulatory Blood‐Pressure Measurements and Mortality , 2018, The New England journal of medicine.

[12]  Neil Chapman,et al.  Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial , 2017, The Lancet.

[13]  A. Cremer,et al.  Abdominal Aortic Calcifications Influences the Systemic and Renal Hemodynamic Response to Renal Denervation in the DENERHTN (Renal Denervation for Hypertension) Trial , 2017, Journal of the American Heart Association.

[14]  G. Schuler,et al.  Blood Pressure Response to Main Renal Artery and Combined Main Renal Artery Plus Branch Renal Denervation in Patients With Resistant Hypertension , 2017, Journal of the American Heart Association.

[15]  C. Ayers,et al.  Hemodynamic and Mechanical Properties of the Proximal Aorta in Young and Middle-Aged Adults With Isolated Systolic Hypertension: The Dallas Heart Study , 2017, Hypertension.

[16]  G. Schuler,et al.  Ultrasound-based renal sympathetic denervation for the treatment of therapy-resistant hypertension: a single-center experience , 2017, Journal of hypertension.

[17]  G. Schuler,et al.  Pulse Wave Velocity Predicts Response to Renal Denervation in Isolated Systolic Hypertension , 2017, Journal of the American Heart Association.

[18]  Deepak L. Bhatt,et al.  Reduced blood pressure-lowering effect of catheter-based renal denervation in patients with isolated systolic hypertension: data from SYMPLICITY HTN-3 and the Global SYMPLICITY Registry , 2016, European heart journal.

[19]  G. Schuler,et al.  Invasive aortic pulse wave velocity as a marker for arterial stiffness predicts outcome of renal sympathetic denervation. , 2016, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[20]  H. Çelik,et al.  The prevalence and distribution of the atherosclerotic plaques in the abdominal aorta and its branches. , 2016, Folia morphologica.

[21]  G. Grassi,et al.  Blood pressure changes after catheter-based renal denervation are related to reductions in total peripheral resistance , 2015, Journal of hypertension.

[22]  G. Chatellier,et al.  Proceedings from the European clinical consensus conference for renal denervation: considerations on future clinical trial design. , 2015, European heart journal.

[23]  Deepak L. Bhatt,et al.  Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. , 2015, European heart journal.

[24]  M. Böhm,et al.  Reduced Effect of Percutaneous Renal Denervation on Blood Pressure in Patients With Isolated Systolic Hypertension , 2015, Hypertension.

[25]  Geoffrey A Head,et al.  European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. , 2014, Journal of hypertension.

[26]  Geoffrey A Head,et al.  European Society of Hypertension position paper on ambulatory blood pressure monitoring. , 2013, Journal of hypertension.

[27]  G. Parati,et al.  Office and 24-h ambulatory blood pressure control by treatment in general practice: the ‘Monitoraggio della pressione ARteriosa nella medicina TErritoriale’ study , 2010, Journal of hypertension.

[28]  Yasmin,et al.  Isolated Systolic Hypertension Is Characterized by Increased Aortic Stiffness and Endothelial Dysfunction , 2007, Hypertension.

[29]  G. Parati,et al.  Lack of placebo effect on ambulatory blood pressure. , 1995, American journal of hypertension.

[30]  R. Kirkpatrick,et al.  Ambulatory Blood Pressure Monitoring , 1993, The Journal of the American Board of Family Medicine.